New combination chemotherapy regimens in the primary treatment of operable breast cancer;Nuove combinazioni chemioterapiche nel trattamento primario del carcinoma mammario operabile

Clinica Terapeutica

Volumn 158, Issue 1, 2007, Pages 55-75

  Conti, F ^a   Sergi, D ^a   Foggi, P ^a   Abbate, M I ^a   Lopez, Massimo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; New agents; Primary chemotherapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; NAVELBINE; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOSENSITIVITY; COMBINATION CHEMOTHERAPY; DRUG DOSE SEQUENCE; FOLLOW UP; HUMAN; MASTECTOMY; PROGNOSIS; REVIEW;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; TAXOIDS; TIME FACTORS;

EID: 33947264116     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Dikson RB, Lippman ME: Cancer of the breast. In: DeVita VT, Hellman S Jr, Rosemberg A (eds): Cancer Principles and Practice of Oncology (ed. 5), Philadelphia, JB Lippincott, 1997; 1599-601
2. Lopez M: Crescita e regressione dei tumori. In Lopez M (ed): Oncologia Medica Pratica (ed. 2), Roma, Società Editrice Universo, 2005; 133-50
3. Gunduz N, Fisher B, Saffer EA: Effect of surgical removal on the growth and kinetics of residual tumour. Cancer Res 1979; 39:3861-5
4. Fisher B, Gunduz N, Saffer FA: Influence of the interval between primary tumour removal and chemotherapy on kinetics and growth of metastases. Cancer Res 1983; 43:1488-92
5. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al.: Recommendations from an International Expert Panel on the use of neoadjuvant (primary) systemic Treatment of operable breast cancer: an update. J Clin Oncol 2006; 24:1940-9
6. Bonadonna G, Veronesi U, Brambilla C, et al.: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990; 82:1539-45
7. Gardin G, Rosso R, Campora E, et al.: Locally advanced non-metastatic breast cancer: analysis of prognostic factors in 125 patients homogenously treated with a combined modalità approach. Eur J Cancer 1995; 31:1428-33
8. Smith IE, Walsh G, Jones A, et al.: High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995; 13:424-9
9. Smith IE, A'Hern RP, Howell A, et al.: Preoperative continuous infusional E Cis F (epirubicin, cisplatin and infusion 5FU) vs conventional AC chemotherapy for early breast cancer: A phase III multicentre randomised trial by the TOPIC Trial Group. Proc Am Soc Clin Oncol 2000; 19:84A (abstr 320)
10. Chollet P, Charier S, Brain E, et al.: Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 1997; 33:862-6
11. Falo C, Moreno A, Benito E, et al.: Primary chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil in operable breast carcinoma. Cancer 2005; 103:657-63
12. Barni S, Piazza E, Frontini L, et al.: Single agent epirubicin as primary chemotherapy in T2-3, N0-N2, M0 breast carcinoma: 6-year follow-up. Oncology 2004; 67:40-7
13. Mouvret-Reynier MA, Abrial CJ, Ferriere JP, et al.: Neoadjuvant FEC 100 for operable breast cancer: eight-year experience at Centre Jean Perrin. Clin Breast Cancer 2004; 5:303-7
14. Conti F, Masi MC, Di Lauro L, et al.: CEF as primary chemotherapy (PTC) in ≥ 3 cm breast cancer patients: long term survival data. Ann Oncol 2005; 16:A7 (suppl 4)
15. Mauriac L, Duran M, Avril A, et al.: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm : Results of a randomised trial in a single centre. Ann Oncol 1991; 2:347-54
16. Scholl SM, Fourquet A, Asselain B, et al.: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours consedered too large for breast conserving surgery : Preliminary results of a randomised trial-S6. Eur J Cancer 1994 ; 30a:645-52
17. Powles TJ, Hickish TF, Makris A, et al.: Randomised trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995; 13:547-52
18. van der Hage JA, van del Velde CJ, Julien JP, et al.: Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001; 19:4224-37
19. Wolmark N, Wang J, Mamounas E, et al.: Preoperative chemotherapy in patients with operable breast cancer: Nine year results from National Surgical Adjuvant Breast and Bowel project B-18. J Natl Cancer Inst Monogr 2001; 30:96-102
20. Buzdar AU, Singletary SE, Theriault RL, et al.: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999; 17:3412-7
21. Green MC, Buzdar AU, Smith T, et al.: Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3 weeks (Q3wk) P therapy (tx) followed by FAC-final results of a prospective phase III randomized trial. Proc Am Soc Clin Oncol 2002; 21:35a (abstr 135)
22. Lewis T, Dimaio T, Patel N, et al.: Weekly paclitaxel as neoadjuvant therapy (NAT) for patients (pts) with T3 and T4 breast cancers (BC): a high incidence of complete responses. Proc Am Soc Clin Oncol 2002; 21:70a (abstr 278)
23. Chakravarthy A, Kelley M, Johnson DH, et al.: Neoadjuvant paclitaxel/radiation for stage II/III breast cancer with correlative molecular markers. Proc Am Soc Clin Oncol 2002; 21:68a (abstr 271)
24. Kimura M: Weekly paclitaxel as neoadjuvant chemotherapy (NAC) for breast cancer (BC). Proc Am Soc Clin Oncol 2003; 22: 77 (abstr 307)
25. Moliterni A, Tarenzi E, Capri G, et al.: Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer. Semin Oncol 1997; 24:10-14 (suppl 17)
26. Moliterni A, Tagliabue P, Tarenzi E, et al.: Non-randomized comparison between primary chemotherapy (PC) with single agent anthracycline (A) or doxorubicin + paclitaxel (AT). Proc Am Soc Clin Oncol 2000; 19:93a (abstr 357)
27. Pouillart P, Fumoleau P, Romieu G, et al.: Final results of a phase II, randomized parallel study of doxorubicin/cyclophosphamide (AC) and doxorubicin/taxol (paclitaxel) (AT) as neoadjuvant treatment of local regional breast cancer. Proc Am Soc Clin Oncol 1999; 18: 73a (abstr 275)
28. Gianni L, Baselga J, Eiermann N, et al.: First report of the European Cooperative Trial in operable breast cancer (ECTO): Effects of primary systemic therapy (PST) on local-regional disease. Proc Am Soc Clin Oncol 2002; 21:34a (abstr 132)
29. Dieras V, Fumoleau P, Romieu G, et al.: Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004; 22:4958-65
30. Magne N, Largillier R, Marcy PY, et al.: Cardiac toxicity assessment in locally advanced breast cancer treated neoadjuvantly with doxorubicin/paclitaxel regimen. Support Care Cancer 2005; 13:819-25
31. Abrial C, Van Praagh I, Delva R, et al.: Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer. Oncologist 2005; 10:242-9
32. Maiorino L, Frasci G, D'Aiuto G, et al.: A two-month cisplatin- epirubicin-paclitaxel (PET) weekly administration is highly effective in large operable breast cancer. Final analysis of a SICOG phase II study. Proc Am Soc Clin Oncol 2005; 16:20s (abstr 566)
33. Bellino R, Cortese P, Danese S, et al.: Primary chemotherapy with sequential epidoxorubicin (E) paclitaxel (P) combination in T2>3cm-T4 breast cancer patients: A phase II study. Proc Am Soc Clin Oncol 2000; 19:131a (abstr 514)
34. Koenig E, Warm M, Breidenbach M, et al.: Neoadjuvant chemotherapy with paclitaxel and epirubicin in patients with primary operable breast cancer. Proc Am Soc Clin Oncol 2002; 21:53b (abstr 2022)
35. Bertone E, Danese S, Richiardi G, et al.: Weekly concomitant administration of epidoxorubicin and paclitaxel as primary chemotherapy for T2 (>3 cm)-T4D breast cancer patients. Proc Am Soc Clin Oncol 2003; 22:72 (abstr 288)
36. Nabell L, Forero A, Urist M, et al.: A phase II trial of preoperative paclitaxel and paraplatin in women with newly diagnosed operable breast cancer. Proc Am Soc Clin Oncol 2005; 16:76s (abstr 794)
37. Shenkier TN, O'Reilly S, Bryce C, et al.: A phase II trial of neoadjuvant doxorubicin/paclitaxel (AT) and cisplatin/paclitaxel (CT) in newly diagnosed patients with locally advanced breast cancer (LABC). Proc Am Soc Clin Oncol 2001; 20 (abstr 1853)
38. Shenkier TN, O'Reilly S, Gelmon K, et al.: A phase II trial of two different sequences of neoadjuvant doxorubicin/paclitaxel (AT) and cisplatin/paclitaxel (CT) in patients with locally advanced breast cancer: Expression of markers over time. Breast Cancer Res Treat 2003; 82:S57 (abstr 246) (suppl 1)
39. Untch M, Konecny G, Ditsch N, et al.: Dose-dense sequential epirubicin-paclitaxel as preoperatiye treatment of breast cancer: Results of a randomized AGO study. Proc Am Soc Clin Oncol 2002; 21:34a (abstr 133)
40. Chollet PJM, Amat S, Penault-Llorca F, et al.: Neoadjuvant docetaxel: 4-year survival outcomes and prognostic factors in patients with operable breast cancer (BC). Proc Am Soc Clin Oncol 2003; 22:48 (abstr 190)
41. Estevez LG, Cuevas JM, Anton A, et al.: Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res 2003; 9:686-92
42. Bines J, Martins RG, Carmo PAO, et al.: Induction chemotherapy with weekly docetaxel (Taxotere®) in unfavourable locally advanced breast cancer (LABC). Eur J Cancer 2001; 37: 6 (abstr 622)
43. Gradishar WJ: Docetaxel as primary chemotherapy in patients with stage III breast cancer. Oncology 1997; 11:15-8
44. von Minckwitz G, Costa SD, Eiermann W, et al.: Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 1999; 17:1999-2005
45. von Minckwitz G, Costa SD, Raab G, et al.: Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase lib study. J Clin Oncol 2001; 19:3506-15
46. Akashi-Tanaka S, Fukutomi T, Watanabe T, et al.: Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy. Int J Cancer 2001; 96:66-73
47. Lee SH, Lee JY, Park J, et al.: Doxorubicin plus Docetaxel as neoadjuvant treatment in patients with large (T > 5 cm), locally advanced carcinoma of the breast. Proc Am Soc Clin Oncol 2004; 22:63 (abstr 746)
48. Marcus E, Burt S, Shiomoto G: The safety of doxorubicin and docetaxel in a phase II trial of neoadjuvant treatment of locally advanced breast cancer. Proc Am Soc Clin Oncol 1999; 18:98a, (abstr 369)
49. Evans T, Gould A, Foster E, et al.: Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in woman with breast cancer: An ACCOG study. J Clin Oncol 2005; 23: 2988-95
50. von Minckwitz G, Raab G, Blohmer JG, et al.: In vivo chemosensitivity adapted neoadjuvant chemotherapy (docetaxel-doxorubicin-cyclophosphamide followed by vinorelbine-capecitabine salvage therapy) in patients with primary breast cancer: Results of the GEPAR-TRIO randomised pilot study. Breast Cancer Res Treat 2003; 82:S54 (abstr 236) (suppl 11)
51. Steger GG, Wenzel C, Djavanmard MP, et al.: Preoperative docetaxel/epidoxorubicin (DE) in primary breast cancer. Proc Am Soc Clin Oncol 1999; 18:118a (abstr 448)
52. Wenzel C, Locker GJ, Schmidinger M, et al.: Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel + granulocyte colony-stimulating factor. Anticancer Drugs 2002; 13:67-74
53. de Matteis A, Nuzzo F, D'Aiuto G, et al.: Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast. A single-center, phase II study. Cancer (Phila), 2002; 94:895-901
54. Reitsamer R, Peintinge F, Prokof E, et al.: Pathological complete response rate comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer. Anticancer Drugs 2005; 16:867-70
55. Luporsi E, Vanlemmens L, Coudert B, et al.: Six cycles of FEC 100 vs 6 cycles of epirubicin-docetaxel (ED) as neoadjuvant chemotherapy in operable breast cancer patients (pts): Preliminary results of randomized phase II trial of GIREC S01. Proc Am Soc Clin Oncol 2000; 19:92a (abstr 355)
56. Miller KD, McCaskill-Stevens W, Sisk J, et al.: Combination versus sequential doxorubicin and Docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 1999; 17:3033-7
57. 0). Breast Cancer Res Treat 2002; 76:S50
58. Blohmer JU, Paepke S, Fleige U, et al.: Dose-intensified, sequential preoperative chemotherapy with epirubicin and Docetaxel in patients with inoperable and non-metastatic breast cancer: A prospective, controlled, multi-center phase II study. Proc Am Soc Clin Oncol 1999; 18:89a (abstr 333)
59. Link JS, Forsthoff CA, Ibarra J, et al.: Dose-dense doxorubicin, docetaxel and cyclophosphamide as sequential neoadjuvant therapy for high-risk breast cancer: A pilot study. Breast Cancer Res Treat 2003; 82:S59 (abstr 254) (suppl 11)
60. Iwata H, Nakamura S, Toi M, et al.: Epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma. Breast Cancer 2005; 12:99-103
61. Cramer EM, Moers C, Zarghooni V, et al.: Neoadjuvant, biweekly, dose-dense chemotherapy with epirubicin and cyclophosphamide followed by docetaxel in primary breast cancer. Proc Am Soc Clin Oncol 2005; 16:82s (abstr 820)
62. Couteau C, Dalenc F, Ferron G, et al.: Neoadjuvant sequential treatment in women with breast cancer: FEC100 then docetaxel : Results in clinical practice. Proc Am Soc Clin Oncol 2004; 23:63 (abstr 749)
63. Ramaswamy B, Povoski SP, Rhoades C, et al.: Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicina in stage II/III breast cancer. Breast Cancer Res Treat 2005; 93:67-74
64. Smith IC, Heys SD, Hutcheon AW, et al.: Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response to docetaxel. J Clin Oncol 2002; 20:1456-66
65. Bear HD, Anderson S, Brown A, et al.: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from the National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2003; 21:4165-74
66. Bear HD, Anderson S, Smith RE, et al.: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 2006; 24:2019-27
67. Henderson IC, Berry DA, Demetri GD, et al.: Improved outcomes from adding sequential paclitaxel but not from the escalating doxorubicin dose in adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21:976-83
68. Citron ML, Berry DA, Cirrincione C, et al.: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leucemia Group B Trial 9741. J Clin Oncol 2003; 21:1431-9
69. Berry DA, Cirrincione C, Henderson IC, et al.: Effects of improvements in chemotherapy on disease-free and overall survival of estrogenreceptor negative, node-positive breast cancer: 20 year experience of the CALGB & U.S. Breast Intergroup. Breast Cancer Res Treat 2004; 88:S17 (abstr 29)
70. Colleoni M, Viale G, Zahrieh D, et al.: Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: A study of preoperative treatment. Clin Cancer Res 2004; 10:6622-8
71. Albain KS, Green SJ, Ravdin PM, et al.: Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 2002; 21:37a (abstr 143)
72. Lee YJ, Doliny P, Gomez-Fernandez C, et al.: Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers. Clin Breast Cancer 2004; 5:371-6
73. Yardley DA, Whitworth P, Greco FA, et al.: Neoadjuvant gemcitabine, epirubicin, and docetaxel (GET): Preliminary results from a multicenter phase II trial in inflammatory and locally advanced breast cancer. Breast Cancer Res Treat 2003; 82:S54 (abstr 237) (suppl 1)
74. Schneeweiss A, Geberth M, Sinn H-P, et al.: The triplet gemcitabine, epirubicin and docetaxel as primary systemic chemotherapy in primary breast cancer T2-4, N0-2, M0: Final primary end point analysis of a multicentric phase I/II trial. Breast Cancer Res Treat 2003; 82:S56 (abstr 242) (suppl 1)
75. Estévez L, Sanchez Rovira P, Domine M, et al.: Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer: a phase II clinical trial with pharmacogenomic study. Proc Am Soc Clin Oncol 2003; 22:61
76. Lebowitz PF, Eng-Wong J, Swain SM, et al.: A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res 2004; 10:6764-9
77. Ro J, Ahn JB, Lee HG, et al.: Docetaxel/capecitabine (TX) vs doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients with stage II/III breast cancer: interim analysis findings from a phase III randomized trial. Breast Cancer Res Treat 2004; 88:S1
78. Andres R, Garcia-Bueno JM, Modolell Catalina Madroñal A, et al.: Phase II multicenter study of nonpegylated liposomal doxorubicin (A) and docetaxel (T) as neoadjuvant chemotherapy in patients with stage II-III and inflammatory breast cancer (BC). Proc Am Soc Clin Oncol 2005; 16:77s (abstr 798)
79. Limentani SA, Brufsky AM, Erban JK, et al.: Phase II study of neoadjuvant docetaxel/vinorelbine followed by surgery and adjuvant doxorubicin/ cuclophosphamide in women with stage II/III breast cancer. Clin Breast Cancer 2006; 6:511-7
80. Slamon DJ, Clark GM, Wong SG, et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-82
81. Slamon DJ, Godolphin W, Jones LA, et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-12
82. Ravdin PM, Chamness GC: The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers - A review. Gene 1995; 159:19-27
83. Cobleigh MA, Vogel CL, Tripathy D, et al.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overxpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-48
84. Vogel CL, Cobleigh MA, Tripathy D, et al.: Efficacy and safety of trastuzumab as a single agent in first line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-26
85. Slamon DJ, Leyland-Jones B, Shak S, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overxpress HER2. N Engl J Med 2001; 344:783-92
86. Norton L, Slamon DJ, Leyland-Jones B, et al.: Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody herceptin in HER2-overxpressing metastatic breast cancer. Proc Am Soc Clin Oncol 1999; 18:127a (abstr 483)
87. Romond EH, Perez E, Bryant J, et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl J Med 2005; 353:1673-84
88. Piccart-Gebhart M, Procter M, Leyland Jones B, et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New Engl J Med 2002; 353:1659-72
89. Burstein HJ, Harris LN, Gelman R, et al.: Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II and III breast cancer: a pilot study. J Clin Oncol 2003; 21:46-53
90. Buzdar AU, Ibrahim NK, Francis D, et al.: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin chemotherapy: results of a randomized trial in Human Epidermal growth factor Receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23:3676-85
91. Wenzel C, Hussian D, Bartsch R, et al.: Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study. J Cancer Res Clin Oncol 2004; 130:400-4
92. Coudert BP, Arnould L, Moreau L, et al.: Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol 2006; 17:409-14
93. Helena CR, Slamon D, DeBruhl ND, et al.: A phase II neoadjuvant study of Taxotere/Carboplatin/Herceptin for locally advanced breast cancer: comparison of breast exam and imaging in assessing tumor response. Breast Canc Res and Treat 2004; 88:S108 (abstr 2094)
94. Chang HR, Slamon D, Chap L, et al.: A phase II neoadjuvant study of taxotere, carboplatin with or without herceptin in locally advanced breast cancer: feasibility and toxicity. Breast Canc Res and Treat 2004; 88:S109 (abstr 2096)
95. Hurley J, Doliny P, Reis I, et al.: Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006; 24:1831-8
96. Jahanzeb M, Brufsky A, Erban J, et al.: Dose-dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support. Proc Am Soc Clin Oncol 2005; 23:26s (abstr 591)
97. Harris L, Burstein HJ, Gelman R, et al.: Preoperative trastuzumab and vinorelbine (HN) is a highly active, well tolerated regimen for HER2 3+/FISH+ stage II/III breast cancer. Proc Am Soc Clin Oncol 2003; 22:22 (abstr 86)
98. Mauri D, Pavlidis N, Ioannidis JPA: Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Nat Cancer Inst 2005; 97:188-94
99. Chevallier B, Roche H, Olivier JP, et al.: Inflammatory breast cancer: Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993; 16:223-8
100. Sataloff DM, Mason BA, Prestipino AJ, et al.: Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: A determinant of outcome. J Am Coll Surg 1995; 180: 297-306
101. Fisher B, Bryant J, Wolmark N, et al.: Effect of preoperative chemotherapy on outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672-85
102. Honkoop AH, van Diest PJ, de Jong JS, et al.: Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998; 77:621-6
103. Kuerer HM, Newman LA, Smith TM, et al.: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17:460-9
104. Pierga JY, Mouret E, Dieras V, et al.: Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 2000; 83:1480-7
105. Ogston KN, Miller ID, Payne S, et al.: A new histological grading system to assess response of breast cancers to primary chemotherapy: Prognostic significance and survival. Breast 2003; 12:320-7
106. Couteau C, Dalenc F, Ferron G, et al.: Neoadjuvant sequential treatment in women with breast cancer: FEC100 then docetaxel : Results in clinical practice. Proc Am Soc Clin Oncol 2004; 23:63 (abstr 749)
107. Ohno S, Toi M, Kuroi K, et al.: the effect of pathologic response of multicenter phase II trial of sequential FEC followed by docetaxel in primary operable breast cancer. Breast Cancer Res Treat 2004; 88,suppl 1
108. Laloni MT, Moura Silva F, Tosello C, et al.: A randomized neoadjuvant chemotherapy (NC) study in advanced breast cancer (BC): AC vs FEC 60. Proc Am Soc Clin Oncol 2004; 23:84 (abstr 832)
109. Chen AM, Meric-Bernstam F, Hunt KK, et al.: Breast conservation after neoadjuvant chemotherapy. Cancer 2005; 103:689-95
110. Chen AM, Meric-Bernstam F, Hunt KK, et al.: Breast conservation after neoadjuvant chemotherapy: The MD Anderson cancer center experience. J Clin Oncol 2004; 22:2303-12
111. Mamounas EP: Sentinel Lymph node biopsy after neoadjuvant systemic therapy. Surg Clin North Am 2003; 83:931-42
112. Pockaj BA, Gray RJ: Surgical management of locally advanced breast cancer. J Clin Oncol 2004; 22:85-91 (Educational Book)
113. Mamounas EP, Brown A, Anderson S, et al.: Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: Results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 2005; 23: 2694-702
114. Mohsin SK, Weiss HL, Gutierrez MC, et al.: Neoadjuvant trastuzumab induces apoptosis in primary breast cancer. J Clin Oncol 2005; 23:2460-8